Santen Pharmaceutical Co Ltd (MEX:4536)
MXN 339.23 0 (0%) Market Cap: 63.30 Bil Enterprise Value: 53.04 Bil PE Ratio: 22.01 PB Ratio: 1.92 GF Score: 92/100

Santen Pharmaceutical Co Ltd R&D Day 1 Transcript

Jul 12, 2019 / NTS GMT
Satoshi Suzuki
Santen Pharmaceutical Co., Ltd. - Senior Corporate Officer, Head of Corporate Development Division & Head of China Business

Satoshi Suzuki, Head of Corporate Development Division. I hope you all will hear me. This is our R&D Day.

In the beginning, let me explain our efforts in this business. This is what we always show you, values and mission statement: Tenki ni sanyo suru, that means we think carefully about what is essential and decide clearly what we should do and act quickly. So each individual activities and in each mission, we need to consider what's the root cause for various challenges and issues. And this is a kind of myth in nature and mainly on pharmaceutical products, and also we want to go beyond the pharmaceutical products as we try to think of what we can do, whether it's a systemic disease, ophthalmology disease, what's the market size and so forth, that's the usual way of thinking. And later, R&D presentation will also follow that kind of approach.

But before that, what is Santen's philosophy in the overall business condition? Let me explain that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot